Meeting
2017 ASCO Annual Meeting
Bevacizumab combined with first-line chemotherapy in elderly patients (≥75 years old) with metastatic colorectal cancer: Final results of the noninterventional CASSIOPEE study.
Authors
Eric Francois
Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France
Eric Francois , Denis Michel Smith , Sophie Gourgou , Sophie Gandon , Florence Rollot , Laurent Mineur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01555762
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3547)
DOI
10.1200/JCO.2017.35.15_suppl.3547
Abstract #
3547
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.
First Author: Pilar Garcia-Alfonso
Poster
2015 ASCO Annual Meeting
PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.
First Author: Thomas Aparicio
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
First Author: Fuxiang Zhou
Poster
2017 ASCO Annual Meeting
Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.
First Author: Mitsukuni Suenaga